#met-enkephalin | Explore Tumblr posts and blogs

botgal · 2 years ago

Text

Concepts for Abno Aberrations that I thought up:

Aberration of Der Freischütz - Kein Meister (translation “No Master”)

An Aberration that’s an amalgamation of several of the “Jack” tales prevalent in fairy tale collections. Jack and the Beanstalk, Jack and the Candlestick, Jack Frost, etc. With the most prominent tale taking the forefront being Jack O’ Lantern. The name being a reference to the old phrase “Jack Of All Trades, Master Of None, Better Than Master Of One”. This Abnormality’s backstory, much like Der Freischütz , involves him making a deal with the Devil after tricking him into climbing a tree that he trapped him in with a cross carved into the bark. Only agreeing to let him down if he promised to make him exempt from going to hell. The Devil agreed and was let back down, but when he died, he had performed so many sinful actions that he was also barred from Heaven. But as a last act of mercy after seeing the man’s betting, or perhaps revenge, the Devil, gloating from a tree that had frozen in winter, and thus he couldn’t carve a cross into, dropped a handful of coals from hell into a pumpkin the man held. Only one of them hit his head on the way down, and his head was eternally caught aflame. Though since he’s dead, perhaps he can’t feel that so much anymore. And those hellfire coals remain the only warmth and light he can really feel in his restless wandering.

In appearance, Kein Meister is dressed in peasant clothing and a coat typical to the era, the shoulders of the coat are constantly covered in frost. His neck, with everything above it having melted, resembles a slightly melted candle, with the semblance of a face flickering in the flame that makes up his head. The only possessions he possesses are a large jack o’ lantern he sits atop that’s filled with coals, a small coin bag he keeps tied to his person, and seemingly innumerable quantities of turnips he seems to be able to pull from inside his coat.

Like Der Freischütz, it’s possible to cut a deal with Kein Meister to get his aid in attacking a breaching Abnormality. If properly paid in Enkephalin, he’ll take a coal from his jack o’ lantern and stuff it into a hollowed turnip, then fling it into the targeted hallway where it will explode in hellfire and cause RED damage to anything inside. But, occasionally (one in seven times) Kein Meister will instead bring out a coin from his purse and toss it, and a chill like the one he feels every day in his limbo torment will fill the room, causing WHITE damage instead.

Attachment work can’t be performed on him, as it’s how he’s ordered for a job. Instinct works on him the least because he’s constantly enduring suffering no matter how many of his base comforts are met (also because he’s technically dead/undead) and all he can really eat are his turnips anyway. Repression work will get good results, but will only work on him at a high enough level, because he’s a trickster who can often weasel his way out of unpracticed people who may want to restrain him. Insight is a medium thing, because even though his environment will never really be comfortable for him, it’s charming in its own way to see the realm he lingers in be decorated to his whimsy (usually by lighting a lot of candles or setting out typical Halloween decor like more, smaller jack o’ lanterns.)

Aberration of Funeral Of The Dead Butterflies - Nursery Of Mori

Based around the opera “Madame Butterfly”, the “Mori” in her name refers to the “Bombyx mori,” the name of the domestic silk moth, as well as “Mori” being a word for death. Previously, she had married a man for love, despite objections from her family, and conceived a child with him before he left her to return to his home, the obtainment of a “proper” wife from his own home already on his mind. She waited for him with their child, putting her whole life on hold so that when he arrived, she could be there to see his return. Only to be heartbroken once she saw he was returning to her home with his new wife by his side. She took the actions to end her own life in despair, but stopped when she heard her child crying. However, the damage had already been done, and with the last of her strength she brought their child to the deceitful “husband”, collapsing with blood staining her clothing only when her child was safely in his arms.

To contrast Funeral’s dapper black funeral suit, Nursery Of Mori dons an all-white shiromuku wedding kimono ensemble, all but for a red “obi” made of multiple layers of wound red thread to symbolize how she met her end. The sleeves are embellished with deep black lines meant to invoke the lines on a silk moth’s wings. And instead of a normal wataboshi, her head is shrouded by two large moth wings to hide her face, from under which one can only occasionally perceive the rustling of wings. She can often be seen kneeling while making something from the thread of her “obi”, which upon close inspection may be seen to be clothes for a child.

It’s recommended that one be at least Attachment Level 3 (the best way to get results from her) and no higher than Justice Level 4 (her worst management method) when working with her, lest they bring her closer to breach. Attempting to perform any Repression work on her will instantly cause a Qliphoth Counter drop, as it’s removing one of her only sources of comfort she has left. Insight and Instinct work both are a 50-50 chance on how well she will respond to the work.

#project moon #lobotomy corporation #wonderlab #abnormalities #funeral of the dead butterflies #der freischütz #aberrations

28 notes · View notes

dsknsk · 2 years ago

Text

Sinners & Arknights character music - Faust x Reconnection

A haughty soul, an unapproachable air and an unparalleled intellect. A riddle she won't allow you to solve unless she lets her guard down.

Under the cut are notes about the drawing, because there is a lot.

The original artwork had very little for me to salvage, so I made something from scratch. The notes on the walls are real chemical notations and excerpts from Faust (in German).

Tyr-Gly-Gly-Phe-Met (YGGFM), C27H35N5O7S = Met-Enkephalin

75909-25-0 = CAS number of Met-Enkephalin

701.32 = molecular weight of Met-Enkephalin

Tyr-Gly-Gly-Phe-Leu (YGGFL), C28H37N5O7 = Leu-Enkephalin

58822-25-6 = CAS number of Leu-Enkephalin

535.27 = molecular weight of Leu-Enkephalin

Chemical notation on the bottom right = the structural correlation between Met-Enkephalin and Morphine (C17H29NO3)

Chemical structure and formula on top right = Dopamine

Chemical structure on the left = Leu-Enkephalin

Literal translation of Faust excerpt on the far left:

Cursed be, from now, the high opinion

Which the mind surrounds itself with!

Cursed be the blinding of the radiance,

Which pushes on our senses!

Cursed be what fools us in our dreams,

The fame, which kept carrying the name!

Cursed be, what allures us as possessions,

As woman and child, as knave and plow!

It's an excerpt from a long 'list' of curses. Here Faust is reflecting on how none of [her] previous life choices and dreams brought [her] happiness or satisfaction.

Literal translation of the Faust excerpt on the middle left:

Woe! Woe!

You have destroyed it,

The beautiful world,

With mighty fist,

It is ruined, it falls,

A halfgod you have slain,

We carry

The fragments into the void

And lament

The lost beauty.

More powerful

Son of the earth

More beautiful

Build it again,

In your own bosom, build it again!

New way of life

Start,

With clear sense,

And new songs

Will be heard from there!

In Faust I, Mephistopheles' minions taunt Faust with these lyrics, encouraging [her] to go out into the world and be that 'More beautiful son of the earth' who destroys and rebuilds the world.

Literal translation of Faust excerpt on the top middle right:

You must know!

From one make ten,

And let the two go,

And three make even,

So you're rich.

Lose the four!

From five and six,

So the witch says,

Make seven and eight,

So it is done:

And nine is one,

And ten is none,

That's the witch's one-times-one!

This is a riddle known as 'Die Hexeneinmaleins', a 'spell' used within Faust itself. It is a 'parody' on the concept of an 'einmaleins', (lit. 'one-times-one'), which is a multiplication table taught to elementary school students. It is also a way of saying "the very basics," similar to "[something] 101" in English.

The way she is holding the broom in front of her makes it somewhat look like she's riding it, like a traditional witch.

#limbus company #please reblog this I put so much effort into this one #sinners x arknights character music

5 notes · View notes

hcs-and-abnormalities · 4 years ago

Note

Howdy stranger! I’m here to bring welcoming cheers and also Der Frei/Clouded Monk requests if you’re okay with it - I’m interested on how you think Der Frei and Clouded Monk get to the point where they’re talking about who confesses to who first. Thank you!

Sorry this took so long! I wanted to do something more than just bullet points for something like this!

Also quick warning for blood but like this is Lob Corp and blood is like rain.

Comission work wasn’t strange to Der Freischütz. If anything, that was one of the main reasons the employees routinely came to him; the other being that he was one of the easier abnormalities to manage. What was strange to him, though, was the target he was to be aiming for. What little information he got and what he saw only made the target stranger. The monster looked like a man, yet also not. A twisted depiction of such? One that used to be human, still looked human, but... wrong? He didn’t know. He just shot.

In order to calm the curiousity that made it’s home in the back of his mind, he one day questioned the employee currently working with him.

“Oh? The Clouded Monk? Yeah, he breached yesterday, not too long after I worked with him either. Feel pretty bad about it too. Normally he’s pretty calm and quiet, yet when I last worked with him, he seemed panicked. Almost on the verge of tears and hugging himself. Kept talking about ‘the demon.’ Felt bad for the guy but there wasn’t much I could do...”

That only piqued the markman’s curiousity more. He was a devil after all... maybe that’s why he felt so strange about this other abnormality? He was similar, in a way. Though, the sources of their hauntings were strikenly different...

And that’s when the marksmen decided he wanted to meet him. Wouldn’t be the first time he interacted with another abnormality (what with his friendships with both Funeral and Red) but this was definitely the first time he initiated it himself.

So, he did something that, technically wasn’t breaching, but might as well have been. You see, his gun can fire anywhere he wishes, as well as creating portals with it. So, all he had to do was think of where he wanted to go, shoot, and walk through.

Of course, the still recuperating monk was... less than thrilled to have the ground in front of him shot with the same bullet that pierced him the other day. He winced, stumbling to his feet and held his staff close to his chest. He shook slightly, though both abnormalities knew this wasn’t from fear.

Der Freischütz cocked his head. Huh, he looked... different. He was much less like a monster, and more so just an ordinary man. Of course, he was unable to see his face (or any skin for that matter), but he could tell from the way he held himself and acted that he was not the creature he shot.He opened his mouth to speak, but was quickly cut off.

“You can’t just... who even are you?” The monk was the one who broke the silence. Despite his shrouded eyes, Der Freischütz knew he was staring daggers right at him.

Frei raised his hand to speak, “Apologies. It was quicker to use my rifle.”

“Quicker to use? Sounds like an excuse you’d use often...” the monk said. Der Freischütz stiffened. “From your reaction, I seem to be correct in that assumption.”

“I didn’t come here to be judged,” Frei said, laying the barrel of the gun on his shoulder, “I just wanted to talk.”

“About what—?”

“...and apologize.”

That caught the monk off guard. So much so that he actually stepped back. “You... want to apologize?”

Frei nodded, then sighed. “I was the one who shot you when you last breached. Remember the bullet?”

“I know it was your bullet. Anyone would know that from the way it shoots straight across the place. No, I’m asking why you of all people would apologize. You’ve never shown remorse before, so why now?”

It was Frei’s turn to step back. “Why would you—?” He paused, “Oh...” Of course the monk knew. Everyone knew in this place. After all, once you see a bullet streak past you, you want to know where and why it was there. That leads to finding his information, then his past... “There’s no privacy in this damn place, is there?”

“Should a murderer like you even get privacy?” The monk had sat back down on the ground. The freeshooter wasn’t as much of a threat as he had thought. Besides, he still was injured enough that he’d rather not stand. “Doing what you do... killing for the fun of it. Even going as far as to shoot your own fiance.”

Frei looked down, hands shaking. This was a mistake. “Truthfully, I was hoping you’d understand.” The monk moved to speak again, but the marksman cut him off, “Of all people, you’d understand what it was like to be tricked.”

Silence.

“...you were tricked?” The monk was the one to break the silence once again. He looked up to the devil, unsure.

Frei moved to sit down as well, tired of towering over the already shorter monk. His gun clattered to the floor next to him.

“When you’re bleeding out, you’re not exactly in the right state of mind...” Frei started. “Besides... it... she told me she would rather herself have... then me being trapped for eternity...”

“In the end, it was her decision.”

The monk stayed quiet for a moment. “Forgive me, I shouldn’t have jumped to conclusions.”

“It’s fine, most do.” Frei said.

“....we really are similar. In the end. I... I still shouldn’t have...” The monk breathed in, then out. His bandaged fingers fumbled around his staff, the rings on the end jingling slightly. He stared at the ground. “Allow me to make it up to you at least.”

“You really don’t have to. It doesn’t matter that much anyway,” Frei sighed, moving to get up and leave. Instead, a bandaged hand grabbed the hem of his cloak.

“But it does matter. How about this, perhaps you could come back tomorrow, and I could get to know you... the real you.”

“And why should I?”

“Because, I can tell you’re just as lonely as I am...” the monk smiled, “You’re not the only one to sense souls. Yours probably should have tipped me off from the start anyway.”

Der Freischütz weighed his options. The monk was telling the truth but... he just met this man, and it had already been a roller coaster of emotions... but... like he said himself, the two of them were very, very similar.

“Okay, it’s a deal then.”

///

The visits continued, luckily without the accusations and random shots at the ground.

Of course, the facility knew of this. They weren’t exactly trying hard to hide their newfound friendship either. The two had been known to both passively breach at times. Both of them just walking down the halls, sometimes taking out some hostile entity to save some poor clerk. After all, despite his dulled numbness to death... Frei didn’t want the monk to suffer from the scent of flesh blood.

Slowy, the two also began to get more... touchy? Not in a weird way, but rather, it became a regular occurrence to see one sleeping on the other. Something so simple yet produced so much enkephalin... It’d be counterproductive to stop this.

“So this dagger was...?” The monk asked. The weapon, sheathed, glinted under the Corporation’s fluorescent lights. A blue dagger with silver accents.

Frei nodded, “She gave it to me. She always talked about how knives weren’t just for violence, but rather for survival as well. She didn’t want me to be in a situation where I wouldn’t be able to cut free from.” His soft smile was evident, as in his time with the monk, he’d become less and less stand-offish towards him. The cowl was pulled down, so his mouth was visible. Or... it was at least visible when opened.

The monk palmed the bandages on his face. Maybe... he wanted to... would it be okay if....? He handed the dagger back to Frei, who pocketed it.

“You seem... troubled today? What is wrong?” Frei leaned against his side. The close warmth made something in the monk’s chest jump.

“Well! I am just fine, thank you.”

“A person who is fine doesn’t insist they are fine,” Frei said, he leaned closer to him. Closing his eyes. He stifled a small laugh when the monk tapped his forehead. “Am I wrong though?”

The monk huffed. “No... I just... I am bot sure how to go about this... never happened to me before.” He started to fuss with the bandages again. Below them, there was a significant red flush that was left unseen.

That made Der Freischütz perk up. The small demon-like tail that the monk adored so much swished eagerly. “What do you mean?” He removed himself, and the monk wished he could pull him back to his side. He had enough wherewithal not too though. “Are your bandages bothering you? Besides, I don’t think I have ever seen you remove them.”

The monk’s hands slipped down, but he said nothing. He opened his mouth to say something, but the words died in his throat before he could. He replaced them with another. “I’m just... I just don’t want people to see my face. At least, not just anyone.”

Der Freischütz nodded, but didn’t pry.

///

Days later, a pounding at his cell’s door woke Frei out of his half-awake state. He shook his head, holding his forehead as an employee ran in, boxes in their hands. “The Clouded Monk has breached! We need you to shoot him again!”

Frei’s body turned cold.

If he refused, the demon could kill people... something the monk would never want to do ever in his life.

But... he had to shoot him.

He had to shoot the person he loved again.

The sudden realization hit him harder than the bullet that pierced his own heart did. So... he did love the monk. Out of instinct, he placed his hand over his chest, where his heart would of been. Nothing beat of course, all that lay there was a gaping hole, but something there still ached. He passed it off as the phantom pains of old wounds. Now, he knew he was wrong.

Before he had a chance to truly respond to the request, the employee had departed. Frei shook. He... he had to do this, right?

///

The monk woke up coughing blood. He hoped it was his own. The other option being...

He tried to stumble away, but was quickly restrained my a strong but kind arm. Soon, it registered that he was laying on someone. He opened his mouth to speak, suddenly aware of the cold air hitting his face. He was quickly quieted though. A soft hand brushing through the hair on his hatless head.

“Der Freischütz?”

“I had to shoot you,” Frei said, his voice quiet and barely audible. “I... I am sorry.”

The monk tried to sit up again, clutching his chest where the bullet hit. He still managed though, getting into an upright position. He still leaned on Frei though, he... he needed someone. “Not your fault. I did tell you I’d rather you shoot me then the alternative.”

Fumbling, the monk realized how the bandages were much looser than before. The ones on his chest were also changed. A look to the corner showed where the bloodstained and torn old ones went.

“You were bleeding rather heavily, and those ones got soaked. Don’t worry, I only removed the ones on your abdomen, nothing else was removed. Sorry about your mouth though. They came loose and I couldn’t find a way to reapply them without restricting your breathing.”

The monk picked up on the slight waver in the marksman’s voice. The unusually quiet and saddened tone he spoke in was much different from his stoic yet soft way of speaking. He also kept clawing at his chest, where his heart would be.

He didn’t know the full details, but he knew nothing lay under his hand there. So why did he...?

In a split second decision ruled by emotion rather than complex thought, the Clouded Monk removed the rest of the bandages on his face. The fell to the ground, folding over themselves.

Freischütz shut his eyes tight, adverting his gaze. In response, the monk gently cupped his cheek, and turned his head back.

Freischütz opened his eyes. They widened after seeing the monk’s face, and the Clouded Monk swore he could see slight sparks under the marksman’s skin.

“Sorry, it’s not much but...”

“Don’t say that!”

Ah, the monk smiled at seeing the cold demon’s face grow hot with blush. He was so... bashful about any emotions he had. Especially if he shouted out those emotions in the heat of the moment.

“I just... thought you only wanted to show someone you trusted—“

Realization dawned on him. “Oh...”

“Oh indeed. Judging by your reaction... Hopefully those feelings aren’t unrequited.” A small stab of worry his the monk’s heart but... after seeing Frei’s face, he knew. And knowing made his own heart beat faster.

Frei sighed, “I... they aren’t by any means... you could probably figure out why I... hated having to...” Der Freischütz shut his eyes tight. Painful memory, or embarrassment at opening his heart? “But... in any case, I guess we both...” Frei leaned his head against the monk’s shutting his eyes. His tail wrapped around the monk’s waist; the fluffy wispy end laid where the bullet hit.

The monk laughed weaky, a smile forming on his face as he leaned back against the devil. “I do love you.”

Frei purred, “And I love you.”

#fic #der freischütz #clouded monk

14 notes · View notes

torturing-characters-101 · 7 years ago

Note

There was a post here a while back about naloxone stripping away even natural opioids, effectively doubling the pain a person is in. Can you elaborate on that? How easy is naloxone to acquire? Is there a reason it isn't used in every torture session ever?

Sure!

Pain is necessary to alert us to harm from injury or illness and prevent us from continually doing stupid things.

But there are a lot of situations in which pain isn’t the most helpful. Once you’re well aware your arm is broken, you definitely don’t need to be reminded of it constantly for the next 6 weeks. Similarly, once you’re immobile and drooling on the floor, you don’t need MORE pain, even if the injury technically warrants it.

Once acute pain has run its useful course, the body can take pity and release a group of neurotransmitters called “endogenous opioids” (specifically, these are called beta-endorphin, met- and leu-enkephalins, and dynorphins). Endogenous opioids can be thought of as chemical “keys” that unlock protein “locks,” called receptor sites (specifically, receptors mu, delta, and kappa).

While the receptor sites are being repeatedly activated (or, “unlocked”) by endogenous opioids, they tell the brain to feel less pain. Whoopee!!

Opioid drugs like heroin, morphine, fentanyl, oxycodone, and hydromorphone are nothing more than chemicals that are so similar to those endogenous opioids that they can activate those same receptors and have the same effect.

Unfortunately, when too many of these sites get activated at once, coma and respiratory depression can occur, causing death. While the body would be really, really hard pressed to produce enough beta-endorphin to do this, it’s actually pretty easy to ingest that much heroin.

That’s where naloxone comes into play. Naloxone is a chemical that is also beautifully shaped to fit right on those receptors…. Except that, once there, it doesn’t actually tell the brain to do anything. Think of it as a key that physically can get in a keyhole, but does not match the lock- the lock isn’t going to turn, and while it’s still in there, no other key can try.

When present, naloxone molecules attach to any free receptor sites, and every time an opioid molecule releases a site, a naloxone molecule swoops in to bind to it. Due to how fast opioids are binding and releasing receptor sites, in only a matter of seconds, most of the receptor sites can have naloxone on them.

This effectively stops an overdose, because with naloxone sitting on all the receptors, even if there’s tons of heroin molecules floating around, they can’t do anything.

Which is great for an overdose, but since the same receptors accept both endogenous opioids and opioid drugs, once naloxone is in place, it blocks both.

To answer your question, based on how it works and clinical trials that proved it works against placebo pain medication as well as opioid drugs, I’m sure naloxone could be a very effective enhancement to a torture scene, as it would prevent the character’s body from decreasing pain itself.

And it’s not too hard to get. Here in the USA, opioid abuse is at an all time high. Which means, basically (and strangely controversially), in some areas you can walk into a health department or pharmacy and walk out with a naloxone kit, no prescription needed usually for less than $20. Sometimes even for free if you say you have a spouse/partner/sibling/child/roommate who abuses opioids. Other areas you’ll need a prescription (which aren’t super difficult to get).

As for why its not used… I don’t know- maybe you’ll have to be the first writer to mention it in a torture scene!

-Ross (macgyvermedical)

#whump reference #writing reference #whump #torture #opioids #drugs #naloxone #narcan

428 notes · View notes

your-dietician · 3 years ago

Text

Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments

New Post has been published on https://depression-md.com/virpax-pharmaceuticals-reports-2021-second-quarter-results-and-recent-developments/

Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments

BERWYN, Pa.–(BUSINESS WIRE)–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the quarter ended June 30, 2021, and other recent developments.

“We continue to advance our product candidate pipeline focused on pain, CNS and anti-viral indications. Two of our product candidates, Epoladerm™ and Probudur™, will utilize an accelerated 505(b)(2) pathway and are currently being funded through proceeds from our initial public offering which closed in February of 2021. Epoladerm, a metered-dose spray film product candidate is currently being evaluated for two indications: acute musculoskeletal pain and chronic pain from osteoarthritis of the knee. For Probudur, our injectable bupivacaine liposomal hydrogel for postoperative pain management, we are currently enhancing the formulation to increase stability for manufacturing and expect that we will be able to extend the patent protection with the newer formulation,” stated Anthony Mack, Chairman and CEO of Virpax.

“For programs where we are developing new chemical entities, such as our Envelta™ product candidate, an intranasal spray for acute and chronic pain, we are performing the IND enabling studies under a Cooperative Research and Development Agreement with the National Center for Advancing Translational Sciences. Recently, we announced that two of the four initial in vitro studies were successfully completed and that once the Envelta IND enabling studies are submitted to the FDA for the current indications, we expect to use the parent IND as a cross reference for additional indications.

For our MMS019 intranasal molecular masking spray, which is being developed as an anti-viral barrier, we recently announced results from an animal study that demonstrated inhibited viral replication and decreased levels of virus in animal brain tissue. We have engaged Syneos Health to work with us on MMS019 in developing the regulatory pathway and trials necessary to file an NDA. A pre-IND briefing package has been submitted to the FDA for this product candidate,” continued Mr. Mack.

“I believe we are making progress in all of our current programs and are laying the foundation for the future. We are working with highly respected clinical research organizations for our IND enabling studies and are pleased with the progress to date. We have engaged Torreya Capital to assist us in our partnering and licensing efforts outside of the U.S. Finally, we announced the addition of two new members to our Board, both of which have exceptional financial and commercialization experience in a move that we believe strengthens our Board as we move forward,” concluded Mr. Mack.

RECENT DEVELOPMENTS

On April 22, 2021, Virpax announced that it has engaged Torreya Capital to advise on partnering and licensing in strategic global markets outside of the U.S.

Subsequent to the end of the quarter, on July 7, 2021, Virpax provided an update on four of its product candidates, Epoladerm™, Probudur™, Envelta™ and MMS019, to the market. https://ir.virpaxpharma.com/prviewer/release_only/id/4766418

Subsequent to the end of the quarter, on July 30, 2021, Virpax announced the appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board of Directors.

SCIENTIFIC ACHIEVEMENTS

On April 5, 2021, Virpax released results of a sciatic nerve preclinical study in rabbits designed to evaluate nerve damage from locally injected Probudur™, Virpax’s liposomal bupivacaine product candidate. Results demonstrated that Probudur™ produced no evidence of motor or sensory nerve damage at a dose that was 10 times higher than free bupivacaine, and that there were no signs of nerve damage.

On April 19, 2021, Virpax announced the results of an animal study model for MMS019, its anti-viral product candidate for respiratory viruses. The animal study demonstrated inhibition of viral replication as well as decreased levels of the virus in animal brain tissue. As a result of the study, Virpax has engaged Syneos Health to assist with the development of a regulatory pathway in addition to the performance of drug development trials required to file an NDA for FDA approval of MMS019.

Subsequent to the end of the quarter, on June 21, 2021, Virpax announced that the Investigational New Drug (or IND) Application enabling studies for Envelta™ being performed under a Cooperative Research and Development Agreement entered into by Virpax and the National Center for Advancing Translational Sciences (or NCATS) for acute and chronic pain, will also be used as a source for INDs for two additional indications, for cancer pain and Post-Traumatic Stress Disorder.

NCATS has commenced the IND enabling studies of Envelta to support Virpax’s future application for clearance from the FDA to initiate Virpax’s first-in-human clinical trials. The Company believes the same Phase I Single Ascending Dose /Multiple Ascending Dose study could be used to advance all three indications.

FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2021 AND 2020

Three Months Ended June 30, 2021 and 2020

Operating Expenses

General and administrative expenses were approximately $2.0 million for the second quarter of 2021, an increase of approximately $0.9 million from last year’s second quarter. The increase was due to legal expenses and an increase in directors and officers insurance (or D&O insurance) expense, partially offset by a decrease in stock-based compensation.

Research and development expenses were approximately $0.3 million for the second quarter of 2021 compared to approximately $0.2 million in last year’s second quarter. The increase in research and development expenses was primarily attributable to an increase in pre-clinical activities related to Epoladerm and Probudur in addition to an increase in regulatory activities for MMS019.

The operating loss for the second quarter of 2021 was approximately $2.3 million, as compared to approximately $1.2 million for the second quarter of 2021.

Six Months Ended June 30, 2021 and 2020

Operating Expenses

General and administrative expenses were approximately $3.3 million for the six months ended June 30, 2021, an increase of approximately $1.8 million from the same period last year. The increase was mainly due to legal expenses and an increase in D&O insurance expense as well as slight increases in both exchange listing fees and accounting consulting costs. This was slightly offset by a decrease in investor relation costs.

Research and development expenses were approximately $1.4 million for the six months ended June 30, 2021 compared to approximately $0.3 million during the same period last year. The increase in research and development expenses was primarily attributable to a milestone payment made to Nanomerics associated with MMS019, as well as increases in pre-clinical activity related to Epoladerm and Probudur as well as an increase in regulatory activities associated with MMS019. This was slightly offset by a decrease in pre-clinical activities associated with Envelta.

Cash Flows

Cash used in operations was approximately $4.9 million for the six months ended June 30, 2021, compared to approximately $0.6 million for the six months ended June 30, 2020. The increase in cash used in operations was primarily the result of the increase in net loss and an increase in prepaid insurance premiums.

Financing Activities

Cash provided by financing activities was approximately $15.3 million during the six months ended June 30, 2021, attributable primarily to net proceeds received from the Company’s initial public offering in February 2021 of approximately $15.8 million, after deducting underwriting discounts and offering expenses. This was offset by repayment in full of the Company’s convertible promissory note of approximately $0.5 million in February 2021. Cash provided by financing activities was $966,000 during the six months ended June 30, 2020, primarily attributable to proceeds of approximately $1,268,900 from the sale of 128,303 shares of the Company’s common stock.

At June 30, 2021, Virpax had cash of approximately $10.5 million.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management product candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal molecular-envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop its PES200 product candidate to manage post-traumatic stress disorder (PTSD) and its MMS019 product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. For more information, please visit www.virpaxpharma.com.

Forward-Looking Statement

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company’s operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

TABLES FOLLOW

VIRPAX PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS

June 30, 2021

December 31, 2020*

(Unaudited)

ASSETS

Current assets

Cash

10,466,774

54,796

Prepaid expenses and other current assets

920,922

18,273

Total current assets

11,387,696

73,069

Deferred financing costs

—

392,337

Total assets

11,387,696

465,406

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Accounts payable and accrued expenses

2,779,866

3,115,924

Notes payable

50,510

543,990

Total current liabilities

2,830,376

3,659,914

Notes payable, net of current portion

21,590

Related party notes payable

1,000,000

Total long-term liabilities

1,021,590

Total liabilities

3,851,966

4,681,504

Commitments and contingencies

Stockholders’ equity (deficit)

Preferred stock, par value $0.00001, 10,000,000 shares authorized, no shares issued and outstanding

—

Common stock, $0.00001 par value; 100,000,000 shares authorized, 4,960,153 shares issued and outstanding as of June 30, 2021; 3,145,153 shares issued and outstanding as of December 31, 2020

Additional paid-in capital

22,906,214

6,431,715

Accumulated deficit

(15,370,534

)

(10,647,844

)

Total stockholders’ equity (deficit)

7,535,730

(4,216,098

)

Total liabilities and stockholders’ equity (deficit)

11,387,696

465,406

* Derived from audited financial statements

VIRPAX PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

For the Three Months Ended June 30, 2021

For the Three Months Ended June 30, 2020

For the Six Months Ended June 30, 2021

For the Six Months Ended June 30, 2020

OPERATING EXPENSES

General and administrative

1,988,972

1,061,850

3,262,544

1,510,835

Research and development

316,565

168,673

1,391,565

335,553

Total operating expenses

2,305,537

1,230,523

4,654,109

1,846,388

Loss from operations

(2,305,537

)

(1,230,523

)

(4,654,109

)

(1,846,388

)

OTHER (EXPENSE) INCOME

Interest expense

(34,049

)

(43,261

)

(64,748

)

(83,891

)

Other income (expense), net

(3,833

)

4,000

(3,833

)

4,000

Loss before tax provision

(2,343,419

)

(1,269,784

)

(4,722,690

)

(1,926,279

)

Benefit from income taxes

—

Net loss

(2,343,419

)

(1,269,784

)

(4,722,690

)

(1,926,279

)

Basic and diluted net loss per share

(0.47

)

(0.41

)

(1.06

)

(0.63

)

Basic and diluted weighted average common stock outstanding

4,958,999

3,086,384

4,454,877

3,065,636

VIRPAX PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

For the Six Months Ended June 30, 2021

For the Six Months Ended June 30, 2020

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss

(4,722,690

)

(1,926,279

)

Adjustments to reconcile net loss to net cash used in operating activities:

Non-cash interest expense

64,748

83,891

Stock-based compensation

691,311

702,681

Common stock issued in payment of consulting services and settlement of accounts payable

–

2,906

Change in operating assets and liabilities:

Prepaid expenses and other current assets

(902,649

)

346,940

Deferred financing costs

–

(73,000

)

Subscription receivable

–

(375,000

)

Accounts payable and accrued expenses

(8,469

)

647,234

Net cash used in operating activities

(4,877,749

)

(590,627

)

CASH FLOWS FROM FINANCING ACTIVITIES

Repayment of notes payable

(493,480

)

–

Proceeds from the issuance of debt

–

72,100

Proceeds from related party notes payable

100,000

–

Repayment of related party notes payable

(100,000

)

Proceeds from the issuance of stock

–

893,900

Offering costs related to initial public offering

(2,216,793

)

–

Proceeds from initial public offering of common stock

18,000,000

–

Net cash provided by financing activities

15,289,727

966,000

Net change in cash

10,411,978

375,373

Cash, beginning of period

54,796

41,536

Cash, end of period

10,466,774

416,909

Supplemental disclosure of cash and non-cash financing activities

Cash paid for interest

34,707

—

Cash paid for taxes

—

Debt issued in payment of consulting services and settlement of accounts payable

—

169,740

Source link

0 notes

moleculardepot · 10 months ago

Text

Adrenorphin Antibody Conjugated to Biotin

Adrenorphin Antibody Conjugated to Biotin Catalog number: B2015828 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 50 ug Molecular Weight or Concentration: N/A Supplied as: Solution Applications: a molecular tool for various biochemical applications Storage: -20 °C Keywords: Adrenorphin, Met(5)-enkephalin, OGF, Opioid Growth Factor Grade: Biotechnology grade. All products are…

View On WordPress

0 notes

evamorina · 5 years ago

Text

Buy GHRP 2 in The UK | Synthetic Peptide | Alpha Helica Peptides

Alpha Helica Peptides is the best wholesaler in the UK. We have the best peptide collection for your scientific research. As we know GHRP-2 peptide is a synthetic analog of met-enkephalin. Also known as growth hormone-releasing peptide-2. GHRP-2 peptide belongs to the group called HGH secretagogues and was developed for its growth hormone. To know more about us, and buy GHRP 2, visit here! t.ly/qO973

#Buy GHRP 2 UK #Buy GHRP 2 #Synthetic Peptide #Alpha Helica Peptides #Research Peptides

0 notes

blueskypeptideposts · 7 years ago

Link

GHRP-6 peptide is a synthetic compound made of six amino acids. GHRP-6 is one of several synthetic met-enkephalin analogs that include unnatural D-amino acids. GHRP-6 can elicit the release of growth hormone (GH).

#ghrp 2 peptide #ghrp-6 peptide

0 notes

themsfish-blog · 7 years ago

Photo

Today I got an abstract tattoo of the chemical compound, met-enkephalin, aka the “runner’s high." wanna know a secret about getting an awesome tattoo? First find an amazing artist like @mikeytatts69 then give him an idea what you want and then let him be creative! First pic is my idea, I told him I wanted rainbow watercolor. The rest was all him! And it turned out amazing! 🏃 #Run #RunnersHigh #tattoo #ChemicalCompound #MetEnkephalin #NewInk (at 816 Tattoo)

#metenkephalin #tattoo #newink #chemicalcompound #runnershigh #run

0 notes

steenpaal · 7 years ago

Text

Gluten exorphin - Wikipedia

Gluten exorphins are a group of opioid peptides formed during digestion of the gluten protein. It has been hypothesized that people with autism and schizophrenia have abnormal leakage from the gut of these compounds, which then pass into the brain and disrupt brain function[1] known as the opioid excess theory or a part of leaky gut syndrome. This is partly the basis for the gluten-free, casein-free diet. Two clinical studies of autism patients who followed this diet have found no evidence of benefit.[2][3] Another found evidence of benefit.[4] Another study suggested the diet may present a greater risk to brain development.[5]

There are four known gluten exorphins with known structure:

Gluten exorphin A5[edit]

Structure: H-Gly-Tyr-Tyr-Pro-Thr-OH

Chemical formula: C24H37N5O9

Molecular weight: 599.64 g/mol

Gluten exorphin B4[edit]

Structure: H-Tyr-Gly-Gly-Trp-OH

Chemical formula: C24H27N5O6

Molecular weight: 481.50 g/mol

Gluten exorphin B5[edit]

Structure: H-Tyr-Gly-Gly-Trp-Leu-OH

Chemical formula: C30H38N6O7

Molecular weight: 594.66 g/mol

Gluten exorphin C[edit]

Structure: H-Tyr-Pro-Ile-Ser-Leu-OH

Chemical formula: C29H45N5O8

Molecular weight: 591.70 g/mol

References[edit]

^ Autism and Schizophrenia: Intestinal Disorders, Cade, et al., Nutritional Neuroscience, Volume 3, Issue 1 February 2000 , pages 57 - 72

^ Popular Autism Diet Does Not Demonstrate Behavioral Improvement, University of Rochester Medical Center, May 19, 2010

^ Christison GW, Ivany K (2006). "Elimination diets in autism spectrum disorders: any wheat amidst the chaff?". J Dev Behav Pediatr. 27 (2 Suppl 2): S162–S171. PMID 16685183. doi:10.1097/00004703-200604002-00015.

^ Knivsberg, AM, Reichelt, KL, Høien, T, Nødland, M. (2002). "A randomised, controlled study of dietary intervention in autistic syndromes". Nutr Neurosci. 5 (4): 251–61. PMID 12168688. doi:10.1080/10284150290028945.

^ Arnold, GL; Hyman, SL; Mooney, RA; Kirby, RS (2003). "Plasma amino acids profiles in children with autism: Potential risk of nutritional deficiencies". Journal of autism and developmental disorders. 33 (4): 449–54. PMID 12959424. doi:10.1023/A:1025071014191.

MOR DOR KOR

Agonists: 3CS-nalmefene

6'-GNTI

8-CAC

18-MC

14-Methoxymetopon

β-Chlornaltrexamine

β-Funaltrexamine

Adrenorphin (metorphamide)

Akuuamicine

Alazocine (SKF-10047)

Allomatrine

Apadoline

Asimadoline

BAM-12P

BAM-18P

BAM-22P

Big dynorphin

Bremazocine

BRL-52537

Butorphan

Butorphanol

BW-373U86

Cebranopadol

Ciprefadol

CR665

Cyclazocine

Cyclorphan

Cyprenorphine

Desmetramadol (desmethyltramadol)

Diamorphine (heroin)

Diacetylnalorphine

Difelikefalin

Dihydroetorphine

Dihydromorphine

Diprenorphine

Dynorphin A

Dynorphin B (rimorphin)

Eluxadoline

Enadoline

Eptazocine

Erinacine E

Ethylketazocine

Etorphine

Fedotozine

Fentanyl

Gemazocine

GR-89696

GR-103545

Hemorphin-4

Herkinorin

HS665

Hydromorphone

HZ-2

Ibogaine

ICI-199,441

ICI-204,448

Ketamine

Ketazocine

Laudanosine

Leumorphin (dynorphin B-29)

Levallorphan

Levomethorphan

Levorphanol

Lexanopadol

Lofentanil

LPK-26

Lufuradom

Matrine

MB-1C-OH

Menthol

Metazocine

Metkefamide

Mianserin

Mirtazapine

Morphine

Moxazocine

MR-2034

N-MPPP

Nalbuphine

Nalbuphine sebacate

NalBzOH

Nalfurafine

Nalmefene

Nalodeine (N-allylnorcodeine)

Nalorphine

Naltriben

Niravoline

Norbuprenorphine

Norbuprenorphine-3-glucuronide

Noribogaine

Norketamine

Oripavine

Oxilorphan

Oxycodone

Pentazocine

Pethidine (meperidine)

Phenazocine

Proxorphan

Racemethorphan

Racemorphan

RB-64

Salvinorin A (salvia)

Salvinorin B ethoxymethyl ether

Salvinorin B methoxymethyl ether

Samidorphan

Spiradoline (U-62,066)

TH-030418

Thienorphine

Tifluadom

Tricyclic antidepressants (e.g., amitriptyline, desipramine, imipramine, nortriptyline)

U-50,488

U-54,494A

U-69,593

Xorphanol

NOP Unsorted Others

Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer)

1 note · View note